Third Wave’s HPV Clinical Trial Achieves Primary Clinical Endpoints

Third Wave Technologies Inc. (NASDAQ: TWTI) announced that the company achieved all primary clinical endpoints in the clinical trial for its human papillomavirus (HPV) tests. The company expects to submit the trial results to the U.S. Food and Drug Administration for both its high-risk and 16/18 genotyping products in April. Third Wave’s 14-type high-risk HPV test demonstrated a negative predictive value greater than the study’s 99% goal.

More: continued here

Filed under: Cervical Cancer on March 15th, 2008